Identification of plasma microRNAs as a biomarker of sporadic Amyotrophic Lateral Sclerosis

Molecular Brain

Volumn 8, Issue 1, 2015, Pages

  Takahashi, Ikuko ^a   Hama, Yuka ^a   Matsushima, Masaaki ^a   Hirotani, Makoto ^a   Kano, Takahiro ^a   Hohzen, Hideki ^b   Yabe, Ichiro ^a   Utsumi, Jun ^a,c   Sasaki, Hidenao ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Obihiro Kosei General Hospital   (Japan)

^c CANCER INSTITUTE   (Japan)

Author keywords

Amyotrophic lateral sclerosis; Biomarker; microRNA

Indexed keywords

BIOLOGICAL MARKER; EPHRIN RECEPTOR A4; MICRORNA; MICRORNA 26B 5P; MICRORNA 3187 5P; MICRORNA 4258; MICRORNA 4299; MICRORNA 4419A; MICRORNA 4496; MICRORNA 4516; MICRORNA 4649 5P; MICRORNA 663B; MICRORNA LET 7F 5P; UNCLASSIFIED DRUG;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DOWN REGULATION; EPHA4 GENE; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA EXTRACTION; RNA STABILITY; UPREGULATION; VALIDATION PROCESS; BLOOD; CASE CONTROL STUDY; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; MIDDLE AGED; PARKINSON DISEASE; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; TIME FACTOR;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; BIOMARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARKINSON DISEASE; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; TIME FACTORS; UP-REGULATION;

EID: 84945139694     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/s13041-015-0161-7     Document Type: Article

References (25)

1. Bartel DP. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell. 2004;116:281-97.
2. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian micro RNA targets. Cell. 2003;115:787-98.
3. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37:495-500.
4. Denil AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary microRNAs by the Microprocessor complex. Nature. 2004;432:231-5.
5. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, et al. Artonoaute2 is the catalytic engine of mammalian RNAi. Science. 2004;305:1437-41.
6. Åkerblom M, Sachdeva R, Barde I, Verp S, Gentner B, Trono D, et al. MicroRNA-124 is a subventricular zone neuronal fate determinant. J Neurosci. 2012;32:8879-89.
7. Zhu H, Bhattacharyya BJ, Lin H, Gomez CM. Skeletal muscle calpain acts through nitric oxide and neural miRNAs to regulate acetylcholine release in motor nerve terminals. J Neurosci. 2013;33:7308-24.
8. Haramati S, Chapnik E, Sztainberg Y, Eliam R, Zwang R, Gershoni N, et al. miRNA malfunction causes spinal motor neuron disease. Proc Natl Acad Sci U S A. 2010;107:13111-6.
9. Shioya M, Obayashi S, Tabunoki H, Arima K, Saito Y, Ishida T, et al. Aberrant microRNA expression in the brains of neurodegenerative diseases. miR-29a decreased in Alzheimer disease brains targets neuron navigator 3. Neuropathol Appl Neurobiol. 2010;36:320-30.
10. De Felice B, Annunziata A, Fiorentino G, Borra M, Biffali E, Coppola C, et al. miR-338-3p is over-expressed in blood, CFS, serum and spinal cord from sporadic amyotrophic lateral sclerosis patients. Neurogenetics. 2014;15:243-53.
11. Freischmidt A, Müller K, Zondler L, Weydt P, Mayer B, von Amim CA et al. Serum microRNAs in sporadic amyotrophic lateral sclerosis. Neuroiol Aging 2015; doi: 10.1016/j.neurobiolaging.2015.06.003.
12. De Felice B, Guida M, Guida M, Coppola C, De Mieri G, Cotrufo R. A miRNA signature in leukocytes from sporadic amyotrophic lateral sclerosis. Gene. 2012;508:35-40.
13. Russell AP, Wada S, Vergani L, Hock MB, Lamon S, Léger B, et al. Disruption of skeltal muscle mitochondrial network genes and miRNAs in amyotrophic lateral sclerosis. Neurobiol Dis. 2013;49:107-17.
14. Williams AH, Valdez G, Moresi V, Qi X, McAnally J, Elliott JL, et al. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science. 2009;326:1549-54.
15. Gallo A, Tandon M, Alevizos I, Illei GG. The Majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One 2012; doi: 10.1371/journal.pone.0030679.
16. Wagner J, Riwanto M, Besler C, Knau A, Fichtlscherer S, Röxe T, et al. Characterization of levels and cellular transfer of circulating lipoprotein-bound microRNAs. Arterioscler Thromb Vasc Biol. 2013;33:1392-400.
17. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108:5003-8.
18. Guerreiro R, Brás J, Hardy J. SnapShot: Genetics of ALS and FTD. Cell 2015;doi: 10.1016/j.cell.2015.01.052.
19. Kawahara Y, Mieda-Sato A. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc Natl Acad Sci U S A. 2012;109:3347-52.
20. miRIAD. www.bioinfo.mochsl.org.br/miriad. Accessed April 14, 2015.
21. Wakabayashi K, Mori F, Kakita A, Takahashi H, Utsumi J, Sasaki H. Analysis of microRNA from archived formalin-fixed paraffin-embedded specimens of amyotrophic lateral sclerosis. Acta Neuropathol Commun 2014; doi. 10.1186/s40478-014-0173-z.
22. Van Hoecke A, Schoonaert L, Lemmens R, Timmers M, Staats KA, Laird AS, et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med. 2012;18:1418-22.
23. Miller RG, Munsat TL, Swash M, Brooks BR. Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology Committee on Research. J Neurol Sci. 1999;169:2-12.
24. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13-21.
25. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md State Med J. 1965;14:61-5.